Harrow, Inc. Proceeds from Other Debt
Harrow, Inc. (HROW) reported Proceeds from Other Debt of $1.00 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-10.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromOtherDebt · last filed 2022-03-10
- Harrow, Inc. proceeds from other debt for the quarter ending 2020-12-31 was $0.00.
- Harrow, Inc. proceeds from other debt for the quarter ending 2020-09-30 was $0.00.
- Harrow, Inc. proceeds from other debt for the quarter ending 2017-12-31 was $0.00.
- Harrow, Inc. proceeds from other debt for fiscal 2020 was $1.00M.
- Harrow, Inc. proceeds from other debt for fiscal 2017 was $15.52M.
| Period end | Proceeds from Other Debt 3 month | Proceeds from Other Debt 6 month | Proceeds from Other Debt 9 month | Proceeds from Other Debt 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $0.00 derived: sum of 2 quarters · filed 2022-03-10 | $1.00M 10-K · filed 2022-03-10 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $1.00M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $1.00M 10-Q · filed 2021-08-10 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $15.52M 10-K · filed 2019-03-12 | ||
| 2017-09-30 | $15.52M 10-Q · filed 2018-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |